Autologous hematopoietic stem cell transplantation for acute myeloid leukemia – single center experience
Autor: | Martin Mistrik, Hrubisko M, D. Horvathova, F Farkas, Bojtarova E, I. Simancikova, L Sopko, Angelika Batorova |
---|---|
Rok vydání: | 2017 |
Předmět: |
Cancer Research
medicine.medical_specialty Transplantation Conditioning medicine.medical_treatment Hematopoietic stem cell transplantation Single Center Transplantation Autologous Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Recurrence hemic and lymphatic diseases Internal medicine Overall survival medicine Humans Autologous transplant Retrospective Studies Chemotherapy business.industry Incidence (epidemiology) Hematopoietic Stem Cell Transplantation Myeloid leukemia Leukemia Myeloid Acute Oncology 030220 oncology & carcinogenesis Toxicity business 030215 immunology |
Zdroj: | Neoplasma. 64:738-744 |
ISSN: | 1338-4317 |
DOI: | 10.4149/neo_2017_512 |
Popis: | We aimed to determine the effect of autologous hematopoietic stem cell transplantation (auto-HSCT) on acute myeloid leukemia (AML) patients as a valid alternative therapeutic option for patients without HLA-compatible donor. This retrospective single center study included 79 patients with AML older than 18 years. In this report, we describe the patient characteristics, engraftment, toxicity of treatment, complications, overall survival, and relapse incidence of 79 patients treated chemotherapy and followed by auto-HSCT. The descriptive statistics was used, and the method of Kaplan and Meier was applied to calculate the actuarial rate of overall survival. The patients achieved an absolute neutrophile count (ANC) of ≥ 0.5 x109/l in between 10 to 40 days; median was 14 days after auto-HSCT. The patients achieved platelet count ≥ 20 x109/l in between 10 to 209 days; median was 19 days after auto-HSCT. Hundred-day mortality after autologous transplant was 6.57% (5/76). The relapse rate was 39.5% (32 patients) and 7 patients (8.6%) were lost from follow-up. On the date of evaluation (April 30, 2016), 48 patients (60.8%) were alive, including 7 (8.6%) patients who are lost from follow-up (not responding to check-up request). The 5-year overall survival (OS) was 60.8%; median overall survival was not reached. The present clinical study has demonstrated safety and efficacy of myeloablative chemotherapy followed by auto-HSCT in the treatment of AML in first remission. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...